Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial)

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.6, 2010-04, pp. : 1035-1037

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dabigatran etexilate for venous thromboembolism: a safety evaluation

By Brown Richard Lip Gregory YH Gallego Pilar

Expert Opinion on Drug Safety, Vol. 13, Iss. 5, 2014-05 ,pp. : 639-647

Informa Healthcare

Access to resources Recommend Favorite

Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal

By Holmes Michael Carroll Christopher Papaioannou Diana

PharmacoEconomics, Vol. 30, Iss. 2, 2012-02 ,pp. : 137-146

Adis International

Access to resources Recommend Favorite

Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism

By Zhang Wei Zhang Wei-Juan Zhu Jin Kong Fan-Cui Li Yan-Yan Wang He-Yao Yang Yuan-Hua Wang Chen

Pharmacogenomics, Vol. 13, Iss. 3, 2012-02 ,pp. : 309-321

Future Medicine

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

By Schulman Sam Majeed Ammar

Drug Safety, Vol. 34, Iss. 6, 2011-06 ,pp. : 449-463

Adis International

Access to resources Recommend Favorite

Warfarin: 6 months don't beat 3 in venous thromboembolism

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite